Seres Therapeutics Entered Into A Non-binding Memorandum Of Understanding With Nestlé Health Science For The Sale Of Seres' VOWST Assets. Under The Terms Of The Pending Agreement, Seres Is Due To Receive Capital Infusions, Including An Upfront Payment
$MCRB
Biotechnology: Pharmaceutical Preparations
Health Care
- Seres anticipates capital infusions, including an upfront payment, enabling the Company to fully retire its debt and extend its cash runway into Q4 2025, pending deal closure and subject to performance under a transition services agreement.
- Future Company focus on advancement of SER-155 and other cultivated oral microbiome therapeutics for medically vulnerable patient populations with potential to address large commercial opportunities.